Optiscan has been featured in Small Caps, highlighting significant progress in its digital pathology study with Australian Clinical Labs (ACL), with more than 80 cases now imaged using the company’s InForm platform.

The article outlines how the study is evaluatingInForm in a high-throughput anatomical pathology environment across a range of human tissue types and disease states. Images generated using InForm are being assessed alongside conventional haematoxylin and eosin-stained slides, helping MedTechCo evaluate image quality, refine the platform with direct input from pathologists and technicians, and build clinical evidence to support product development and future regulatory submissions. The study is also creating a growing digital image library to support training and broaden understanding of how InForm may be applied across different pathology workflows.

CEO and Managing Director Dr. Camile Farah said: “Successfully imaging more than 80 cases through in just six months is an incredible achievement that demonstrates the maturity and commercial readiness of our platform and highlights the potential impact real-time cellular imaging can have in transforming pathology.”

He added: “Digital pathology is rapidly reshaping the way tissue is analysed and the collaboration with ACL gives us the opportunity to be part of this process—results to date showcase how real-time, slide-free microscopic imaging can complement existing pathology workflows.”

Read the full article here.